Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.

Journal of Neural Transmission
H HallG Sedvall


Affinities and regional densities of the D1- and D2-dopamine receptor subtypes were studied in the human post-mortem brain in vitro using the two selective radioligands 3H-SCH 23390 and 3H-raclopride. 3H-Raclopride binding was confined to the caudate nucleus, the putamen and the substantia nigra, while 3H-SCH 23390 bound to cortical regions as well. The binding of 3H-SCH 23390 was reduced by a low concentration of ketanserin, indicating binding to 5-HT2 receptors in addition to the D1-dopamine receptors. The endogenous neurotransmitter dopamine interacted potently both with the D1-dopamine receptor and the D2-dopamine receptor, displaying two affinity states for each subtype. The distribution of the dopamine receptor subtypes obtained in the present in vitro investigation is in agreement with data obtained with 11C-SCH 23390 and 11C-raclopride in positron emission tomographic studies in human volunteers.


Jan 11, 1979·Nature·J W Kebabian, D B Calne
Jan 1, 1986·Acta Pharmacologica Et Toxicologica·H HallE Jerning
Jan 1, 1986·Advances in Experimental Medicine and Biology·P H Andersen, E B Nielsen
Jan 1, 1986·Advances in Experimental Medicine and Biology·G SedvallC Halldin
Jan 1, 1986·Advances in Experimental Medicine and Biology·T M DawsonJ K Wamsley
Jul 1, 1987·Archives of General Psychiatry·L FardeG Sedvall
Jun 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·L FardeG Sedvall
Feb 5, 1985·European Journal of Pharmacology·T M DawsonJ K Wamsley
Apr 1, 1974·The Journal of Comparative Neurology·O LindvallU Stenevi
Jan 1, 1983·Annual Review of Neuroscience·I CreeseS E Leff
Jul 15, 1983·European Journal of Pharmacology·J Hyttel
Sep 1, 1980·Analytical Biochemistry·P J Munson, D Rodbard
Dec 3, 1984·Life Sciences·J C Stoof, J W Kebabian
Oct 30, 1984·European Journal of Pharmacology·D W SchulzR B Mailman
Feb 17, 1984·European Journal of Pharmacology·D R Gehlert, J K Wamsley
Apr 23, 1982·European Journal of Pharmacology·S BischoffR Ortmann
Dec 5, 1980·European Journal of Pharmacology·S BischoffJ Krauss

❮ Previous
Next ❯


Jan 1, 1994·European Archives of Psychiatry and Clinical Neuroscience·G SedvallL Farde
Jul 6, 1993·European Journal of Pharmacology·N MohellD M Jackson
Feb 1, 1993·Neurochemistry International·J De Keyser
Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·H HallG Sedvall
Mar 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·H HallG Sedvall
Apr 4, 2002·Nuclear Medicine and Biology·Michael KassiouBernard Maziere
Dec 24, 1998·Nuclear Medicine and Biology·H HallG Sedvall
Apr 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideo TsukadaEdward F Domino
Apr 28, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideo TsukadaEdward F Domino
Aug 1, 1997·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·S M MoerleinM J Welch
Dec 8, 2009·Nuclear Medicine Communications·Kenji IshibashiKiichi Ishiwata
Mar 1, 1993·Pharmacology & Toxicology·H HallG Sedvall
Dec 1, 1993·Pharmacology & Toxicology·S O OgrenK Angeby-Möller
Feb 22, 1991·Science·T Sawaguchi, P S Goldman-Rakic
Sep 9, 2011·The Journal of Experimental Biology·Jedediah TresslerMichael Smotherman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.